Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · Real-Time Price · USD
1.660
+0.010 (0.61%)
Jul 3, 2025, 1:00 PM - Market closed
Company Description
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States.
It’s lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair.
Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
Biomea Fusion, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Apr 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Michael J. Hitchcock |
Contact Details
Address: 1599 Industrial Road San Carlos, California 94070 United States | |
| Phone | 650 980 9099 |
| Website | biomeafusion.com |
Stock Details
| Ticker Symbol | BMEA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001840439 |
| CUSIP Number | 09077A106 |
| ISIN Number | US09077A1060 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael J. M. Hitchcock Ph.D. | Interim Chief Executive Officer and Director |
| Ramses M. Erdtmann | Co-Founder, President, Chief Operating Officer and Director |
| Heow Tan | Chief Technology and Quality Officer |
| Naomi Cretcher | Chief People Officer |
| Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Chemistry |
| Dr. Stephan Morris M.D. | Chief Development Officer |
| Ravi Upasani Ph.D. | Executive Vice President of Intellectual Property |
| Dr. Juan Pablo Frias M.D. | Chief Medical Officer |
| Caroline Perez- Dupont J.D. | Senior Vice President of Contracts |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2025 | SCHEDULE 13G | Filing |
| Jun 20, 2025 | 8-K | Current Report |
| Jun 18, 2025 | 8-K | Current Report |
| Jun 18, 2025 | 424B5 | Filing |
| Jun 17, 2025 | 424B5 | Filing |
| Jun 17, 2025 | 8-K | Current Report |
| Jun 13, 2025 | 8-K | Current Report |
| May 5, 2025 | 10-Q | Quarterly Report |
| May 5, 2025 | 8-K | Current Report |
| Apr 28, 2025 | ARS | Filing |